Open AccessApremilast for the treatment of psoriasis and psoriatic arthritis
Author(s) -
Chaplin Steve
Publication year - 2013
Publication title -
future prescriber
Language(s) - English
Resource type - Journals
eISSN - 1931-2261
pISSN - 1468-9871
DOI - 10.1002/fps.102
Subject(s) - apremilast , psoriatic arthritis , psoriasis , medicine , dermatology , pharmacology , drug , arthritis , immunology
Apremilast, an orally active inhibitor of phosphodiesterase 4 that inhibits several inflammatory cytokines, is being developed for the treatment of psoriasis and psoriatic arthritis. This Drug profile reviews the clinical data to date. Copyright © 2013 John Wiley & Sons, Ltd.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom